Erythropoietin Drug Market Share, Size, Forecast 2022
                     Also known as hematopoietic, erythropoietin drug is defined as a glycoprotein hormone that  
controls erythropoiesis. Erythropoiesis is defined as the production of red blood cells (RBC). 
 A new report on the global erythropoietin drug market, published by Market Research Future  
(MRFR), estimates that this market can visualize expansion at 9.5% CAGR between 2017 and 
 2023.
The most significant market driving factor for the global Erythropoietin Drug Market is the  
increasing prevalence of diseases like cancer and various renal diseases. The increasing  
investment in medical research & development (R&D) and introduction of new drugs are also  
carrying forward the market growth. Noth just new drugs but the market is also getting strong  
due to the introduction of several new erythropoietin drug combinations. Other factors  
contributing to the global erythropoietin price growth include different government initiatives  
for research and a wider pool of patients being covered due to the introduction of new drug  
combinations.
Market Segmentation
The global erythropoietin drug market segmentation encompasses application, end-user, and  
product type. MRFR’s take on the market surveys various facets of the market in-depth.
The application-based segmentation of this market covers the Human Immunodeficiency  
Virus (HIV), oncology, renal diseases, and others.
In the context of end-user, the market has been segmented into hospital and pharmacy.  
Regarding product type, the market has been segmented into biosimilars, first-generation  
formulation, and second-generation formulation.
Key Players
Big players in the global erythropoietin drug market 3SBio (China), Amgen (USA), Biocon  
(India), Biosidus (Argentina), Boehringer Ingelheim (USA), Celltrion Inc. (South Korea),  
Dahua Pharmaceutical (China), Emcure Pharmaceuticals (India), Hoffmann-La Roche  
(Switzerland), Hospira (USA), Intas Pharmaceuticals (India), Johnson & Johnson (USA),  
Kyowa Hakko Kirin (Japan), LG Life Sciences Ltd. (South Korea), and Teva  
Pharmaceutical Industries Ltd. (Israel).
Regional Segmentation
A geographical outlining of the global erythropoietin for sale covers North America, Europe, 
 Asia Pacific, and the Middle East & Africa (MEA).
North America holds the largest share in the global market due to continuously increasing  
number of the cancer patient, technological advancement in the medical sector, availability of  
advanced medical services, governmental initiatives for research, and patient suffering from  
renal diseases in North America. USA and Canada generate maximum market revenue in this  
region. Some of the key market players are based in the USA.
In Europe, the market is growing primarily due to the same reasons as in North America.  
Amendments in reimbursement policies and the growing healthcare sector are also 
contributing  to the market growth. Due to the availability of advanced medical facilities, 
Western Europe is  a bigger regional market than Eastern Europe. The most powerful country-
specific markets in  Europe are France, Germany, Italy, Spain, and the UK. An inspection of 
the remaining  countries in Western Europe featured in this report speculate the huge 
contribution to market  revenue from some other countries in this region with a sizable 
revenue from Eastern Europe  too.
During the forecast period, the gains for Asia Pacific market can rise high, making it the 
fastest-  growing regional market. The factors benefitting the market growth in this region are 
increased  penetration of healthcare services and expanding patient population in countries 
like China and  India. Moreover, the increased government effort to improve healthcare in 
these countries is  creating new growth opportunities for the market. Other important country-
specific markets in  this region are Australia, Japan, and South Korea. An analysis of the 
remaining countries in the  Asia Pacific region featured in this report estimates the huge 
contribution to market revenue  from some other countries.
The MEA region holds the lowest share in the global market due to poor medical facilities and 
 lack of skilled professionals.
Latest Industry News
 GlaxoSmithKline (GSK) has started the marketing activities in Japan to launch a new oral  
drug called daprodustat. Daprodustat is meant to cure anemia associated with chronic  
kidney disease (CKD), which is caused by a deficiency in erythropoietin. Daprodustat is  
also expected to be an alternative to many erythropoiesis-stimulating agents (ESAs) that  
are injected into the body of the patient. 21 AUG 2019
About US:
Market Research Future (MRFR) enable customers to unravel the complexity of various  
industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR),  
Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research &  
Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited), 
 99 Hudson Street,5Th Floor, New York,
New York 10013